Our study indicates that low serum albumin can increase the risk of symptomatic or asymptomatic HT after intravenous thrombolytic therapy, and the effect remained significant even after adjusting for age, Atrial fibrillation, and NIHSS. The gene discussed is ALB; the disease is hematocrit.